Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Inhibikase Therapeutics (IKT) has provided an update.
Inhibikase Therapeutics, Inc. is confronting a legal challenge from Pivot Holding LLC, which is claiming $1.625 million plus interest over alleged breach of contract concerning milestone payments under a 2012 agreement. Despite Pivot’s demands, Inhibikase maintains that no payment is due and is prepared to aggressively defend its position while pursuing counterclaims. Amidst this dispute, the company’s forward-looking statements highlight ongoing clinical trials, regulatory efforts, and financial needs, emphasizing the inherent risks and uncertainties in their outcomes.
For a thorough assessment of IKT stock, go to TipRanks’ Stock Analysis page.
